BICO Group AB Class B · OMXSTO:BICO

BICO Group AB Class B — Cellink — Investor Day (2021)

98 slides from BICO Group AB Class B's investor day presentation, 2021

  1. Slide 1: Welcome to our first digital Capital Markets Day

    Slide 1: Welcome to our first digital Capital Markets Day

    WELCOME TO OUR FIRST DIGITAL CAPITAL MARKETS DAY! © CELLINK 2021, All rights reserved.

  2. Slide 2: Agenda

    Slide 2: Agenda

    AGENDA Welcome Break (5 min) Break (5 min) Isabelle Ljunggren Introduction to Bioprinting Introduction to Artur Aira & Cecilia Edebo Industrial Solutions Introduction to the future of medicine Dr. Holger Eickhoff Dr. Robert Langer The BIO MDX Series Q&A session Bioconvergence agenda and Dr. Héctor M

  3. Slide 3: How to use GoToWebinar

    Slide 3: How to use GoToWebinar

    Expand control options Maximize window size How to use GoToWebinar Ask questions and chat with the presenter © CELLINK 2021, All rights reserved.

  4. Slide 4: Q&A session

    Slide 4: Q&A session

    Q&A SESSION PARTICIPATE BY SENDING YOUR QUESTIONS TO THE QUESTION BOX Write your questions here! © CELLINK 2021, All rights reserved.

  5. Slide 5: Introduction to the future of medicine

    Slide 5: Introduction to the future of medicine

    CELLINK CAPITAL MARKETS DAY 2021 INTRODUCTION TO THE FUTURE OF MEDICINE Dr. Robert Langer MIT and co-founder of Moderna, Scientific Advisor CELLINK © CELLINK 2021, All rights reserved.

  6. Slide 6: Introduction to the future of medicine

    Slide 6: Introduction to the future of medicine

    INTRODUCTION TO THE FUTURE OF MEDICINE Dr. Robert Langer MIT and co-founder of Moderna, Scientific Advisor CELLINK © CELLINK 2021, All rights reserved.

  7. Slide 7: Bioconvergence agenda and strategic focus areas 2021

    Slide 7: Bioconvergence agenda and strategic focus areas 2021

    CELLINK CAPITAL MARKETS DAY 2021 BIOCONVERGENCE AGENDA AND STRATEGIC FOCUS Erik Gatenholm AREAS 2021 CEO, CELLINK © CELLINK 2021, All rights reserved. © CELLINK 2021, All rights reserved.

  8. Slide 8: Bioconvergence agenda and strategic focus areas

    Slide 8: Bioconvergence agenda and strategic focus areas

    BIOCONVERGENCE AGENDA AND STRATEGIC FOCUS AREAS Erik Gatenholm, CEO © CELLINK 2021, All rights reserved.

  9. Slide 9: Passion – Inspiration – Persistence

    Slide 9: Passion – Inspiration – Persistence

    PASSION – INSPIRATION – PERSISTENCE 2016 2021 CELLINK = bioprinting CELLINK = CELLINK Group, Business Areas and Group Companies Bioprinting Bioconvergence 7 employees 700 employees TAM, $1.4Bn+ TAM, $150Bn+ 20 laboratories 2,000+ laboratories 5 publications 1,700+ publications Market Cap MSEK 645 Ma

  10. Slide 10: Modern healthcare challenges that shape the future of bioconvergence

    Slide 10: Modern healthcare challenges that shape the future of bioconvergence

    MODERN HEALTHCARE CHALLENGES THAT SHAPE THE FUTURE OF BIOCONVERGENCE. Source: https://innovationisrael.org.il/en/reportchapter/bio-convergence © CELLINK 2021, All rights reserved.

  11. Slide 11: Preventing future pandemics requires early detection

    Slide 11: Preventing future pandemics requires early detection

    Preventing future pandemics is contingent on the early detection and monitoring of infectious diseases. © CELLINK 2021, All rights reserved.

  12. Slide 12: Most drugs in development fail in clinical trials

    Slide 12: Most drugs in development fail in clinical trials

    9 out of 10 drugs in development fail in clinical trials. It can take 10 to 12 years to develop a new drug at a cost of more than $2Bn. © CELLINK 2021, All rights reserved.

  13. Slide 13: Organ donation waiting lists and transplant failure

    Slide 13: Organ donation waiting lists and transplant failure

    While 108,000 chronically ill patients wait on organ donation lists, only 39,000 transplants are performed in the U.S. each year. For the lucky few who do find a donated organ, however, the rejection failure rate is an astounding 50%. Sources: organdonor.gov (U.S. government on organ donation and tr

  14. Slide 14: Bioconvergence is the future of healthcare

    Slide 14: Bioconvergence is the future of healthcare

    BIOLOGY + TECHNOLOGY BIOCONVERGENCE IS THE FUTURE OF HEALTHCARE © CELLINK 2021, All rights reserved.

  15. Slide 15: Bioconvergence to form the future base of medicine

    Slide 15: Bioconvergence to form the future base of medicine

    • BIOCONVERGENCE TO FORM THE FUTURE BASE OF MEDICINE AND TO RESHAPE THE GLOBAL HEALTH INDUSTRY Bioconvergence connects various technologies from the fields of biology and engineering to identify and develop precise, personalized and effective medical solutions Technological Bioconvergence Technologi

  16. Slide 16: The Bio Revolution

    Slide 16: The Bio Revolution

    THE BIO REVOLUTION* Human health is one of the most significant domains where biological advances are being applied. Biology is already helping save lives through innovative treatments tailored to our genomes and microbiomes. In the future, we estimate that almost half of the global disease burden c

  17. Slide 17: The solution is found in bioconvergence

    Slide 17: The solution is found in bioconvergence

    THE SOLUTION IS FOUND IN BIOCONVERGENCE Drug discovery 3D Cell culturing Regenerative medicine CRISPR & Gene editing - tissue printing Diagnostics and Single cell omics Optics and Imaging Biopharmaceuticals biological sensors © CELLINK 2021, All rights reserved.

  18. Slide 18: The bioconvergence company

    Slide 18: The bioconvergence company

    THE BIOCONVERGENCE COMPANY ? ? ? ? ? ? ? ? ? ? Bioprinters & Bioinks ? © CELLINK 2021, All rights reserved.

  19. Slide 19: The bioconvergence company

    Slide 19: The bioconvergence company

    THE BIOCONVERGENCE COMPANY Bioprocessing Reagents Microscopy Live cell imaging POC Cell culture OMICS Genomics Biosensors Proteomics Bioreactors Bioinformatics Diagnostics NGS Bioprinters & Bioinks Single cell sorting AI Robotics Liquid handling Consumables Cell line development © CELLINK 2021, All

  20. Slide 20: It is the era of bioconvergence

    Slide 20: It is the era of bioconvergence

    IT IS THE ERA OF BIOCONVERGENCE Serving our customers in the best possible way by offering market leading workflows Diagnostics Single cell printing & Live-cell imaging Extrusion based sorting bioprinting Assays Tissues Omics BIOPRINTING BIOSCIENCES Sample Prep. INDUSTRIAL SOLUTIONS Light based Bior

  21. Slide 21: Bioconvergence market

    Slide 21: Bioconvergence market

    BIOCONVERGENCE MARKET APPLICATION AREAS $150Bn+ Diagnostics Single cell printing & Live-cell imaging Extrusion based sorting bioprinting Assays Tissues Omics BIOPRINTING BIOSCIENCES Sample Prep. INDUSTRIAL SOLUTIONS Light based Bioreactors bioprinting Laser based bioprinting NGS Library Multiplex OE

  22. Slide 22: The bioconvergence workflow

    Slide 22: The bioconvergence workflow

    THE BIOCONVERGENCE WORKFLOW 1. Patient diagnosis 2. Sample analysis 3. Cells harvested 4. Single cell 5. Cell expansion isolation 10a. Personalized 9. Live cell analysis 8. High throughput 7. Cells bioprinted 6. Cell counting treatment plan screening 11a. Drug efficacy 12a. Successful 10. New drug 1

  23. Slide 23: 3D bioprinting for chronic lymphocytic leukemia culture model

    Slide 23: 3D bioprinting for chronic lymphocytic leukemia culture model

    3D Bioprinting allows the establishment of long-term 3D culture model for chronic lymphocytic leukemia cells • Chronic Lymphocytic Leukemia (CLL) represents the most common leukemia in the western world and remains incurable. Leukemic cells organize and interact in the lymphoid tissues, however what

  24. Slide 24: Strategic focus areas 2021

    Slide 24: Strategic focus areas 2021

    STRATEGIC FOCUS AREAS 2021 Strengthen our position as the bioconvergence company in the world through strong business areas and dedicated group companies M&A and tech Financials Customers People Sustainability development Deliver on financial targets Best customer care, design, quality Happy and mot

  25. Slide 25: Strategic focus areas 2021

    Slide 25: Strategic focus areas 2021

    STRATEGIC FOCUS AREAS 2021 Area Focus 2021 M&A and tech • Active customer centric M&A agenda development agenda • Develop and capitalize on our strong R&D and tech development agenda (Group synergies) • Continue collaboration through partnerships with Academia, research organizations and Strengthen

  26. Slide 26: World-leading customers in four segments

    Slide 26: World-leading customers in four segments

    WORLD-LEADING CUSTOMERS IN FOUR SEGMENTS Universities & research Pharmaceutical Diagnostic Cosmetic organizations companies companies companies/others • Human implants (e.g., bone), • Cancer research (in vitro, • Multiplex assays, lateral flow tests, • Toxicity and cosmetic tests on biomaterials res

  27. Slide 27: Partnerships and collaborations exploring the bioconvergence agenda

    Slide 27: Partnerships and collaborations exploring the bioconvergence agenda

    PARTNERSHIPS AND COLLABORATIONS EXPLORING THE BIOCONVERGENCE AGENDA PARTNERSHIPS 2020-2021 SIGNIFICANT COLLABORATIONS May 2020: collaboration with AstraZeneca to utilize CELLINK’s 3D-bioprinting technology for liver organoid culture. ETH summer school program focused on 3D printing. June 2020: CELLI

  28. Slide 28: Strategic focus areas 2021

    Slide 28: Strategic focus areas 2021

    STRATEGIC FOCUS AREAS 2021 Area Focus 2021 • Integration strategy for acquisitions, initial 100-day plan People • Create a shared digital workplace for the Group and encourage knowledge sharing Happy and motivated team • Continuous monitoring employee satisfaction • Training and development on Group

  29. Slide 29: Financial summary Q1 2021 and M&A update

    Slide 29: Financial summary Q1 2021 and M&A update

    CELLINK CAPITAL MARKETS DAY 2021 FINANCIAL SUMMARY Q1, 2021 AND M&A UPDATE Gusten Danielsson CFO, CELLINK © CELLINK 2021, All rights reserved.

  30. Slide 30: Financial summary and M&A update

    Slide 30: Financial summary and M&A update

    FINANCIAL SUMMARY AND M&A UPDATE Gusten Danielsson, CFO © CELLINK 2021, All rights reserved.

  31. Slide 31: Long term financial targets 2019-2022

    Slide 31: Long term financial targets 2019-2022

    STRATEGIC FOCUS AREAS 2021 LONG TERM FINANCIAL Financials TARGETS 2019-2022 Deliver on financial targets Outcome 2020 CELLINK’s objective is to achieve an annual organic sales growth of Organic growth Organic growth was 48% (77%) >35%, supplemented by strategic acquisitions. Outcome 2020 EBITDA marg

  32. Slide 32: High organic growth, strengthened gross margin and strategic acquisitions

    Slide 32: High organic growth, strengthened gross margin and strategic acquisitions

    HIGH ORGANIC GROWTH, STRENGTHENED GROSS MARGIN AND STRATEGIC ACQUISITIONS Q1: January-March 2021  Net sales amounted to MSEK 129.5 (38.0), which corresponds to an increase of 241% (55) compared to the corresponding period previous year, of which 62% (25) was organic growth.  EBITDA amounted to MSE

  33. Slide 33: High organic growth in combination with accretive M&A

    Slide 33: High organic growth in combination with accretive M&A

    Organic High organic growth SEK per MSEK NET SALES & SALES PER SHARE (LTM) Growth Quarter share in combination with 500 62% 10,00 450 9,00 accretive M&A 400 8,00 350 7,00 300 6,00 250 5,00 200 4,00 150 3,00 100 2,00 50 1,00 0 0,00 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 Q1 FY2018/19 FY2019/20 2021 © CELLINK 2021

  34. Slide 34: Positive trend for gross margin

    Slide 34: Positive trend for gross margin

    MSEK GROSS PROFIT & MARGIN (LTM) Positive trend for 400 85% gross margin, closing 350 at 73%, LTM 300 80% 250 75% 200 70% 150 100 65% 50 0 60% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 Q1 FY2018/19 FY2019/20 2021 © CELLINK 2021, All rights reserved.

  35. Slide 35: Increasing revenue from consumables and services

    Slide 35: Increasing revenue from consumables and services

    CONSUMABLES AND PROPORTION OF PRODUCT Increasing REVENUES OF CONSUMABLES & SERVICES AND revenue from MSEK 100 PROPORTION OF SALES FROM SERVICES (LTM) 20,0% consumables and 90 18,0% services 80 16,0% 70 14,0% 60 12,0% 50 10,0% 40 8,0% 30 6,0% 20 4,0% 10 2,0% 0 0,0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q5 Q1 Consu

  36. Slide 36: Organic growth per region Q1 2021

    Slide 36: Organic growth per region Q1 2021

    ORGANIC GROWTH PER REGION Q1, 2021 vs. Q1, 2020 (Share of sales, Q1 2021) NORTH EUROPE ASIA AMERICA 36% 33% (41%) 92% (14.5%) (43%) RoW 11% (1.5%) © CELLINK 2021, All rights reserved.

  37. Slide 37: Convertible bonds and Class B share issue

    Slide 37: Convertible bonds and Class B share issue

    STRATEGIC FOCUS AREAS 2021 M&A and tech CELLINK issued senior unsecured convertible bonds convertible development Strengthen bioconvergence position into Class B shares and a Class B share issue in an overall amount of SEK 3.0 billion on March 12, 2021 • Assuming full conversion, the Bonds will enta

  38. Slide 38: Customer centric M&A agenda

    Slide 38: Customer centric M&A agenda

    STRATEGIC FOCUS AREAS 2021 CUSTOMER CENTRIC M&A AGENDA M&A and tech development Strengthen bioconvergence position CELLINK invests in entrepreneurs’ enthusiasm and passion for what they do. We aim to find and acquire companies that are built on determined people with a strong desire to create the fu

  39. Slide 39: Successful integration of acquired companies

    Slide 39: Successful integration of acquired companies

    STRATEGIC FOCUS AREAS 2021 SUCCESSFUL INTEGRATION OF ACQUIRED COMPANIES M&A and tech development Strengthen bioconvergence position EV/sales multiples EV/sales multiples EV/sales multiples EV/sales multiples EV/sales multiples (in 29 months) (in 19 months) (in 7 months) 15 8 4 4 5 6 3 3 4 10 ~ 3.7x

  40. Slide 40: Focus 2021

    Slide 40: Focus 2021

    STRATEGIC STRATEGIC FOCUS AREAS 2021 FOCUS AREAS 2021 M&A and tech Financials development Deliver on financial Strengthen bioconvergence targets FOCUS 2021 position Continue our active and Deliver on our Identify cost efficiency customer centric M&A financial targets. synergies in the Group. agenda.

  41. Slide 41: Introduction to Biosciences

    Slide 41: Introduction to Biosciences

    CELLINK CAPITAL MARKETS DAY 2021 INTRODUCTION TO BIOSCIENCES Dr. Jonas Schöndube Business Area Manager Biosciences © CELLINK 2021, All rights reserved.

  42. Slide 42: Introduction to Biosciences

    Slide 42: Introduction to Biosciences

    INTRODUCTION TO BIOSCIENCES Dr. Jonas Schöndube Business Area Manager © CELLINK 2021, All rights reserved.

  43. Slide 43: Business Area Biosciences

    Slide 43: Business Area Biosciences

    BUSINESS AREA BIOSCIENCES Market segments Customer base Main competitors Cell Line Development, Berkeley Lights; BeckmanCoulter, Biopharma & Biotech companies, Live-cell imaging, Single-Cell Omics, Sartorius; Becton, research organizations Liquid Handling Dickinson and Company (BD) TAM Product offer

  44. Slide 44: Major trends – market drivers

    Slide 44: Major trends – market drivers

    MAJOR TRENDS – MARKET DRIVERS 1 2 3 4 Biosimilars/bio-betters Cell and Gene Therapy Software/Automation Single-cell multi omics More and more Revolutionary More value by software Most cell analysis is companies develop therapeutic approaches on existing hardware. or will be single-cell biopharmaceut

  45. Slide 45: Application areas and offering

    Slide 45: Application areas and offering

    STRATEGIC FOCUS AREAS 2021 Customers Best customer care, design, quality and supply chain in the industry APPLICATION AREAS AND OFFERING Cell line development Liquid handling Live-cell imaging Single-cell omics © CELLINK 2021, All rightsreserved.

  46. Slide 46: Cell line development

    Slide 46: Cell line development

    STRATEGIC FOCUS AREAS 2021 CELL LINE DEVELOPMENT M&A and tech development Strengthen bioconvergence Traditional workflow 96-well plate 24-well plate 24 deep well plate position Plate Imaging 50-250 µl 350-800 µl 2-3 ml Transfection First round Second round Proof of clonality Complicated upscaling pr

  47. Slide 47: Single-cell or COVID-19 sequencing workflows

    Slide 47: Single-cell or COVID-19 sequencing workflows

    STRATEGIC FOCUS AREAS 2021 SINGLE-CELL OR COVID-19 M&A and tech development Strengthen bioconvergence SEQUENCING WORKFLOWS position f.sight™/UP.SIGHT™ seqWell I-DOT™ C.WASH Single-cell Reagents Liquid DNA purification Sequencing and isolation handling data analysis NGS library preparation Option for

  48. Slide 48: High-content screening with cell-based assays

    Slide 48: High-content screening with cell-based assays

    HIGH-CONTENT SCREENING WITH CELL-BASED ASSAYS C.WASH CELLCYTE X Grow cells Treat cells Downstream Wash cells Monitor cells e.g., fluorescent analysis staining © CELLINK 2021, All rights reserved.

  49. Slide 49: Focus 2021

    Slide 49: Focus 2021

    FOCUS 2021 1 2 3 Accelerate Applications and Software revenue growth, Workflows development especially for consumables and • Cell line • The CELLINK reagents. development Biosciences SW • Single-cell team is growing Whilst keeping multi-omics heavily. profitability positive. • High content screening

  50. Slide 50: © CELLINK 2021, All rights reserved.

    Slide 50: © CELLINK 2021, All rights reserved.

    © CELLINK 2021, All rights reserved.

  51. Slide 51: Break

    Slide 51: Break

    BREAK NEXT SESSION: BIOPRINTING © CELLINK 2021, All rights reserved.

  52. Slide 52: Introduction to Bioprinting

    Slide 52: Introduction to Bioprinting

    CELLINK CAPITAL MARKETS DAY 2021 Artur Aira INTRODUCTION Business Area Manager Bioprinting TO BIOPRINTING Cecilia Edebo Managing Director CELLINK Bioprinting © CELLINK 2021, All rights reserved.

  53. Slide 53: Introduction to Bioprinting

    Slide 53: Introduction to Bioprinting

    INTRODUCTION TO BIOPRINTING Artur Aira, Business Area Manager and Cecilia Edebo, Managing Director CELLINK Bioprinting © CELLINK 2021, All rights reserved.

  54. Slide 54: Business Area Bioprinting

    Slide 54: Business Area Bioprinting

    BUSINESS AREA BIOPRINTING Market segments Product offering Customer base Pharmaceutical-, cosmetics- and Light based bioprinting Research: regenerative medicine, Laser based bioprinting industrial food companies, 3D cell culture, drug research Extrusion based bioprinting med tech industry, academia

  55. Slide 55: Major trends – market drivers

    Slide 55: Major trends – market drivers

    MAJOR TRENDS – MARKET DRIVERS 1 2 3D Bioprinting Tissue Models 3 4 Microfluidics Personalized Medicine © CELLINK 2021, All rights reserved.

  56. Slide 56: Application areas and offering

    Slide 56: Application areas and offering

    STRATEGIC FOCUS AREAS 2021 Customers Best customer care, design, quality and supply chain in the industry APPLICATION AREAS AND OFFERING Extrusion based Light based bioprinting Laser based bioprinting bioprinting Bioinks Tissues © CELLINK 2021, All rights reserved.

  57. Slide 57: Long-term 3D bioprinting market potential

    Slide 57: Long-term 3D bioprinting market potential

    Long-term 3D bioprinting market potential The cell culture The 3D printing market market is expected to is expected to reach reach $33Bn by 2025 between $1.4-4bn by with a CAGR 2024 with a CAGR of +11.8% annually. 20-35% annually. Bioprinting today Including extrusion, ink jet, light based, etc. Sca

  58. Slide 58: 3D cell culture methods

    Slide 58: 3D cell culture methods

    3D Cell Culture Scaffold-free Methods Scaffold-based methods Primarily spheroids and organoids cultured in media. Defined as being “grown in the presence of a support” Could be simple like ECM or TME scaffolding (gel) around a simple spheroid or organoid. Or scaffolding could also be used to support

  59. Slide 59: The evolution of 3D bioprinting

    Slide 59: The evolution of 3D bioprinting

    STRATEGIC FOCUS AREAS 2021 The evolution of M&A and tech development Strengthen bioconvergence Organs for position 3D bioprinting implant To scale organs Our Customers Mini-organs Tissues “The Biologist” Scaffold-free 3D Techniques Scaffold-based methods Traditional monolayer 2D cell culture © CELLI

  60. Slide 60: The increase in tissue model testing

    Slide 60: The increase in tissue model testing

    STRATEGIC FOCUS AREAS 2021 Sustainability Develop a sustainability agenda REDUCTION IN ANIMAL TESTING THE INCREASE FASTER DRUG DEVELOPMENT PROCESS IN TISSUE MODEL TESTING SUPERIOR MODELS OF HUMAN TISSUE OPPORTUNITIES WITH IN-VITRO TOXICOLOGY MARKET TISSUE MODELS IN 3D BIOPRINTING DEVELOPING THE RIGH

  61. Slide 61: Bipartisan legislation to modernize testing standards

    Slide 61: Bipartisan legislation to modernize testing standards

    STRATEGIC FOCUS AREAS 2021 U.S. representatives have introduced bipartisan Sustainability Develop a sustainability agenda legislation to modernize testing standards, end mandatory animal testing, and lower drug prices “This reform would allow the use of the nonclinical test methods most likely to pr

  62. Slide 62: MatTek – MelanoDerm – Skin Lightening

    Slide 62: MatTek – MelanoDerm – Skin Lightening

    STRATEGIC FOCUS AREAS 2021 MatTek – MelanoDerm – Skin Lightening Sustainability Develop a sustainability agenda Transfer tissues from Incubate 1 hour at Apply test materials to agarose to assay medium 37°C, 5% CO₂ apical surface of tissues Harvest tissues for Stop exposure by rinsing Repeat applicat

  63. Slide 63: The bioprinting assortment

    Slide 63: The bioprinting assortment

    THE BIOPRINTING ASSORTMENT TM TM BIOINK BIO X LUMEN X TM TM TM INKREDIBLE BIO X6 HOLOGRAPH X © CELLINK 2021, All rights reserved.

  64. Slide 64: Focus 2021

    Slide 64: Focus 2021

    STRATEGIC STRATEGIC FOCUS AREAS 2021 FOCUS AREAS 2021 FOCUS 2021 Sustainability M&A and tech Develop a sustainability development agenda Strengthen bioconvergence position 1 2 3 Continue with strategic Continue our mission to Explore the commercial acquisitions and contribute to decrease of opportun

  65. Slide 65: © CELLINK 2021, All rights reserved.

    Slide 65: © CELLINK 2021, All rights reserved.

    © CELLINK 2021, All rights reserved.

  66. Slide 66: The BIO MDX series

    Slide 66: The BIO MDX series

    CELLINK CAPITAL MARKETS DAY 2021 Dr. Héctor Martínez CTO, CELLINK THE BIO MDX SERIES Cecilia Edebo Managing Director CELLINK Bioprinting © CELLINK 2021, All rights reserved.

  67. Slide 67: The BIO MDX series

    Slide 67: The BIO MDX series

    THE BIO MDX SERIES Dr. Héctor Martínez, CTO, CELLINK Cecilia Edebo, Managing Director CELLINK Bioprinting © CELLINK 2021, All rights reserved.

  68. Slide 68: The BIO MDX series: ushering in a new era of bioprinting

    Slide 68: The BIO MDX series: ushering in a new era of bioprinting

    STRATEGIC FOCUS AREAS 2021 M&A and tech development Ushering in a new era of bioprinting Strengthen bioconvergence position THE BIO MDX SERIES High Precise control at Unique modular throughput multi-scale resolution technology Bioprinting from single-cell to spheroid to capabilities bulk tissue © CE

  69. Slide 69: Key application areas

    Slide 69: Key application areas

    STRATEGIC FOCUS AREAS 2021 Strength across KEY APPLICATION AREAS M&A and tech development Strengthen bioconvergence position 3D Cell-based assays Cosmetic & Tissue engineering for high throughput wound healing drug screening Superior insights Personalized implants Reduced dependency on for drug disc

  70. Slide 70: Total climate control for utmost sterility

    Slide 70: Total climate control for utmost sterility

    STRATEGIC FOCUS AREAS 2021 M&A and tech Total climate control development for utmost sterility Strengthen bioconvergence position Onboard intuitive & powerful software Multi-channel bioprinting High throughput Max build volume: with capacity for up to 82.5x36x15 cm 27 microplates

  71. Slide 71: Modular technology

    Slide 71: Modular technology

    STRATEGIC FOCUS AREAS 2021 M&A and tech development Strengthen bioconvergence position Modular technology Compatible with single cell & Up to 6 Modular Printheads spheroid printing Up to 2 Bulk Liquid Dispensers Up to 2 sciDROP NANO Dispensers Up to 2 sciDROP PICO Dispensers Dynamic printhead temper

  72. Slide 72: Featured workflow

    Slide 72: Featured workflow

    STRATEGIC FOCUS AREAS 2021 FEATURED WORKFLOW M&A and tech development Strengthen bioconvergence position The end-to-end solution for batch biofabrication of personalized medical devices Load cells in cartridges and Automated Stimulate tissue Tissue Tissue maturation Personalized initiate human biopr

  73. Slide 73: How we work and interact with our engaged customers and partners

    Slide 73: How we work and interact with our engaged customers and partners

    CELLINK CAPITAL MARKETS DAY 2021 HOW WE WORK AND INTERACT Dr. Itedale Namro Redwan CSO Bioprinting WITH OUR ENGAGED CUSTOMERS AND PARTNERS Mariana Andrade Head of Customer success © CELLINK 2021, All rights reserved.

  74. Slide 74: How we work and interact with our engaged customers and partners

    Slide 74: How we work and interact with our engaged customers and partners

    HOW WE WORK AND INTERACT WITH OUR ENGAGED CUSTOMERS AND PARTNERS Itedale Namro Redwan, CSO Bioprinting and Mariana Andrade, Head of Customer success © CELLINK 2021, All rights reserved.

  75. Slide 75: Customers

    Slide 75: Customers

    STRATEGIC FOCUS AREAS 2021 Customers Best customer care, design, quality and supply chain in the industry © CELLINK 2021, All rights reserved.

  76. Slide 76: Customers

    Slide 76: Customers

    STRATEGIC FOCUS AREAS 2021 Customers Best customer care, design, quality and supply chain in the industry © CELLINK 2021, All rights reserved.

  77. Slide 77: Customers

    Slide 77: Customers

    STRATEGIC FOCUS AREAS 2021 Customers Best customer care, design, quality and supply chain in the industry © CELLINK 2021, All rights reserved.

  78. Slide 78: More customer spotlights

    Slide 78: More customer spotlights

    More customer spotlights on www.cellink.com/ customer-spotlights © CELLINK 2021, All rights reserved.

  79. Slide 79: Introduction to Industrial Solutions

    Slide 79: Introduction to Industrial Solutions

    CELLINK CAPITAL MARKETS DAY 2021 INTRODUCTION TO INDUSTRIAL Dr. Holger Eickhoff SOLUTIONS Business Area Manager Industrial Solutions © CELLINK 2021, All rights reserved.

  80. Slide 80: Introduction to Industrial Solutions

    Slide 80: Introduction to Industrial Solutions

    INTRODUCTION TO INDUSTRIAL SOLUTIONS Dr. Holger Eickhoff Business Area Manager © CELLINK 2021, All rights reserved.

  81. Slide 81: Business Area Industrial Solutions

    Slide 81: Business Area Industrial Solutions

    BUSINESS AREA INDUSTRIAL SOLUTIONS Market segments Sales model Main competitors Diagnostics, Biosensors, Instruments, consumables, services Tecan, ATS, HP, Sanmina, Nordson, Single-Cell Omics and Liquid Handling and contract manufacturing 10xGenomics, Nanocellect Product offering Customer base TAM s

  82. Slide 82: Major trends – market drivers

    Slide 82: Major trends – market drivers

    MAJOR TRENDS – MARKET DRIVERS 1 2 3 4 Molecular Diagnostics Precision medicine COVID Testing Software/Automation & Wearables Most cell analysis is or will be More and more companies The pandemic has broken the Disease management with single-cell analysis in the near launch COVID tests. Our barrier o

  83. Slide 83: Application areas and offering

    Slide 83: Application areas and offering

    STRATEGIC FOCUS AREAS 2021 Customers Best customer care, design, quality and supply chain in the industry APPLICATION AREAS AND OFFERING Medical Devices Diagnostics Sensors /Wearables Single Cell Omics Drug Delivery

  84. Slide 84: Core Technology

    Slide 84: Core Technology

    Next-Generation Technology for Low Volume Precision Dispensing SCIENION is the only company capable of dispensing both biological reagents and viable single cells at an industrial scale Precision Dispensing in pL to µL Range Single Cell Isolation and Handling Core Technology sciDROP NANO sciDROP PIC

  85. Slide 85: A scalable approach to next generation of diagnostics

    Slide 85: A scalable approach to next generation of diagnostics

    A SCALEABLE APPROACH TO NEXT GENERATION OF DIAGNOSTICS ADVANCED AUTOMATION Cutting-edge robotics and automated solutions for manufacturing of diagnostic devices including lateral flow and microfluidics © CELLINK 2020, All rights reserved.

  86. Slide 86: Lateral flow device manufacturing

    Slide 86: Lateral flow device manufacturing

    LATERAL FLOW DEVICE MANUFACTURING We provide production automation solutions for lateral flow device manufacturing using only very limited amounts of precious bioreagents. Our standard modules give you the flexibility to make a wide range of products with a single automation line, without compromisi

  87. Slide 87: Medical device manufacturing through high quality automation

    Slide 87: Medical device manufacturing through high quality automation

    MEDICAL DEVICE MANUFACTURING THROUGHHIGH QUALITY AUTOMATION Specialized in modular desktop solutions for the automated production and processing of micro components and medical device products. Surface Treatment Dispensing (Plasma, spray coating, UV curing) (Array printing, membrane striping) Testin

  88. Slide 88: Core Technology: cellenONE

    Slide 88: Core Technology: cellenONE

    Core Technology: cellenONE cellenONE allows high-throughput, automated dispensing of individual cells from cell suspensions onto any substrate Benefits Technical Specifications Dispensing technology Acoustic dispensing • Real-time, high accuracy single cell isolation Single Cell Accuracy and dispens

  89. Slide 89: cellenCHIP

    Slide 89: cellenCHIP

    cellenCHIP A consumable to miniaturize and automate our customers’ single cell sample preparation Offer full solutions to our Enable development of customers (system + Fast market access: Allows tomorrow’s leading single cell consumables + reagents) for miniaturization of existing (multi)omics proto

  90. Slide 90: Bioconvergence in Industrial Solutions: POC/lateral flows

    Slide 90: Bioconvergence in Industrial Solutions: POC/lateral flows

    STRATEGIC FOCUS AREAS 2021 BIOCONVERGENCE IN INDUSTRIAL SOLUTIONS M&A and tech development Strengthen bioconvergence 1. POC/LATERAL FLOWS position Increased life expectancy, increased frequency of chronic Early and efficient disease e.g., cancer, heart disease medical intervention Technological and

  91. Slide 91: Bioconvergence in Industrial Solutions: single cell genomics

    Slide 91: Bioconvergence in Industrial Solutions: single cell genomics

    STRATEGIC FOCUS AREAS 2021 BIOCONVERGENCE IN INDUSTRIAL SOLUTIONS M&A and tech development Strengthen bioconvergence 2. SINGLE CELL/HIGH PRECISION GENOMICS MARKET position The genomic revolution, the dramatic decline in the cost Two of the other fields developing alongside biotechnology and increase

  92. Slide 92: Focus 2021

    Slide 92: Focus 2021

    STRATEGIC FOCUS AREAS 2021 FOCUS 2021 M&A and tech development Strengthen bioconvergence position 1 2 3 Combined Launch the cellenCHIP Focus on development of SCIENION/Ginolis/ and proteoCHIP. a unique cloud and CELLENION offering for Enter the single cell bioinformatics offering for early detection

  93. Slide 93: Recorded presentations

    Slide 93: Recorded presentations

    RECORDED PRESENTATIONS www.cellink.com/investors

  94. Slide 94: Q2 report 2021 to be released August 18, 2021

    Slide 94: Q2 report 2021 to be released August 18, 2021

    Q2-REPORT 2021 TO BE RELEASED: AUGUST 18, 2021 © CELLINK 2021, All rights reserved.

  95. Slide 95: Investor relations inquiries

    Slide 95: Investor relations inquiries

    FOR MEETING REQUESTS AND INVESTOR RELATIONS RELATED INQUIRIES: ir@cellink.com © CELLINK 2021, All rights reserved.

  96. Slide 96: Thank you!

    Slide 96: Thank you!

    THANK YOU! © CELLINK 2021, All rights reserved.

  97. Slide 97: Contact info

    Slide 97: Contact info

    CONTACT INFO ERIK GATENHOLM, CEO eg@cellink.com, phone: +1 (650) 515 5566 GUSTEN DANIELSSON, CFO gd@cellink.com, phone: +1 (857) 332 2138 ISABELLE LJUNGGREN, HEAD OF COMMUNICATIONS il@cellink.com, phone: +46 708 300 890 www.cellink.com/investors © CELLINK 2021, All rights reserved.

  98. Slide 98: Disclaimer

    Slide 98: Disclaimer

    DISCLAIMER You must read the following before continuing. The following applies to this document and the information provided in this presentation by CELLINK AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection with such

Source: Internet Archive copy of bico.com

More decks from BICO Group AB Class B

All 22 BICO Group AB Class B decks